Samsung Bioepis Demonstrates Equivalence in Phase 1 and 3 Trials of Keytruda Biosimilar
Global Phase 1 Pharmacokinetic and Phase 3 Efficacy Assessments
First Public Phase 3 Results Among Keytruda Biosimilars Worldwide
"Clinical Trials Expected to Be Completed Within This Year"
Samsung Bioepis announced on June 29 that it has demonstrated equivalence to the original drug in both global Phase 1 and Phase 3 clinical trials of ‘SB27’, a biosimilar candidate of Keytruda.
The reference drug for SB27, Keytruda (ingredient name: pembrolizumab), is an immune-oncology therapy developed by MSD and is used to treat various cancers, including non-small cell lung cancer, melanoma, and head and neck cancer. With projected 2025 sales of USD 31.7 billion (approximately KRW 46 trillion), it is considered a global blockbuster drug.
Since 2024, Samsung Bioepis has been conducting global Phase 1 and Phase 3 trials simultaneously in patients with non-small cell lung cancer, comparing the pharmacokinetics, efficacy, safety, and immunogenicity of SB27 and Keytruda.
In the Phase 1 trial, conducted in four countries including Korea with 163 participants, pharmacokinetic equivalence was confirmed based on the area under the concentration-time curve (AUC), which evaluates the degree of drug exposure in the body.
Subsequently, in the Phase 3 trial with 555 participants across 14 countries, the primary endpoint was set as the objective response rate (ORR) at week 24. The results showed that SB27 demonstrated equivalent efficacy to the original drug. The safety and immunogenicity profiles were also similar between the two treatment groups. Samsung Bioepis explained that these results represent the first public disclosure of Phase 3 clinical data in the global Keytruda biosimilar development race.
Donghoon Shin, Vice President and Head of Clinical Development at Samsung Bioepis, stated, "By demonstrating equivalence between SB27 and the original drug, we have secured a significant achievement that showcases our global biosimilar development capabilities. We will continue our efforts to enhance treatment accessibility for patients in the immuno-oncology field through biosimilars."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Samsung Bioepis has adopted an overlap strategy by conducting Phase 1 and Phase 3 trials concurrently, accelerating the development timeline for SB27. The company plans to complete both trials within this year.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.